N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia.

  title={N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia.},
  author={Frank Jessen and Natascha Fingerhut and Alois M Sprinkart and Kai-Uwe K{\"u}hn and Nadine Petrovsky and Wolfgang Maier and H Schild and Wolfgang Block and Michael Wagner and F Tr{\"a}ber},
  journal={Schizophrenia bulletin},
  volume={39 1},
UNLABELLED BACKGROUND : Imbalance of glutamatergic neurotransmission has been proposed as a key mechanism underlying symptoms of schizophrenia. The neuropetide N-acetylaspartylglutamate (NAAG) modulates glutamate release. NAAG provides a component of the proton magnetic resonance spectrum (1H-MRS) in humans. The signal of NAAG, however, largely overlaps with its precursor and degrading product N-acetylaspartate (NAA) that by itself does not act in glutamatergic neurotransmission. METHODS We… CONTINUE READING

From This Paper

Figures and tables from this paper.


Publications citing this paper.
Showing 1-10 of 23 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

Effects of Nacetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR

AC Fricker, MH Mok, R de la Flor

Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry • 2008

Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology • 2008

Similar Papers

Loading similar papers…